Innovating Works

CHIESI

Desconocido
PREMSTEM: Brain injury in the premature born infant stem cell regeneration research network CHIESI FARMACEUTICI SPA participó en un H2020: H2020-SC1-BHC-2018-2020 This project will provide new knowledge regarding the best regimen, timing, dose, and route of administration of human mesenchymal stem cell...
2019-12-06 - 2025-12-31 | Financiado
MS4Drug: An Innovative Mass Spectrometry Based Workflow for Drug Discovery CHIESI FARMACEUTICI SPA tramitó un H2020: H2020-MSCA-IF-2018 Pulmonary Arterial Hypertension (PAH) is a life-threatening condition; even if treated, patients only have a 5-year survival rate of less th...
2019-04-30 - 2021-06-30 | Financiado
FAIR-PARK-II: Conservative iron chelation as a disease modifying strategy in Parkinson s disease a multicentric... CHIESI FARMACEUTICI SPA participó en un H2020: H2020-PHC-2014-2015 Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Exces...
2015-04-14 - 2021-10-31 | Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes CHIESI FARMACEUTICI SPA participó en un FP6: RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado
PRO- ACTIVE: Physical Activity as a Crucial Patient Reported Outcome in COPD CHIESI FARMACEUTICI SPA tramitó un FP6: Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have l...
2009-09-01 - 2016-05-31 | Financiado
PRO- ACTIVE: Physical Activity as a Crucial Patient Reported Outcome in COPD CHIESI FARMACEUTICI SPA tramitó un FP7: Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have l...
Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes CHIESI FARMACEUTICI SPA participó en un FP7: Rationale The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma thi...
Financiado
NEUROINFLAMMATION: nEUROinflammation CHIESI FARMACEUTICI SPA participó en un FP7: Neuroinflammation is a hallmark of multiple sclerosis and ischemic stroke. Investigating neuroinflammation as a common theme in neurological...
Financiado
EUPATI: European Patients Academy on Therapeutic Innovation CHIESI FARMACEUTICI SPA participó en un FP7: "The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ aware...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.